Holen Sie sich die Stockscreener-App
14.88
1.59%
-0.24
Schlusskurs vom Vortag:
$15.12
Offen:
$15.16
24-Stunden-Volumen:
74,752
Relative Volume:
0.93
Marktkapitalisierung:
$312.02M
Einnahmen:
$217.21M
Nettoeinkommen (Verlust:
$-33.72M
KGV:
-9.1829
EPS:
-1.6204
Netto-Cashflow:
$25.63M
1W Leistung:
-9.10%
1M Leistung:
+0.81%
6M Leistung:
-5.94%
1J Leistung:
-14.09%
1-Tages-Spanne:
$14.60
$15.16
1-Wochen-Bereich:
$14.60
$16.46
52-Wochen-Spanne:
$12.96
$20.90
Amarin Corp Adr Stock (AMRN) Company Profile
Firmenname
Amarin Corp Adr
Sektor
Telefon
353 1 6699 020
Adresse
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Compare AMRN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
14.88 | 312.02M | 217.21M | -33.72M | 25.63M | -1.6204 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-10-25 | Herabstufung | Jefferies | Buy → Hold |
| 2023-01-06 | Hochstufung | Jefferies | Hold → Buy |
| 2022-05-06 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-05 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-31 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-31 | Herabstufung | Jefferies | Buy → Hold |
| 2020-03-31 | Hochstufung | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Hochstufung | Goldman | Neutral → Buy |
| 2020-03-02 | Eingeleitet | Cowen | Outperform |
| 2020-02-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-01-06 | Eingeleitet | JP Morgan | Neutral |
| 2019-12-16 | Herabstufung | Stifel | Buy → Hold |
| 2019-11-20 | Eingeleitet | Oppenheimer | Underperform |
| 2019-11-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-11-15 | Bestätigt | SVB Leerink | Outperform |
| 2019-10-31 | Eingeleitet | Aegis Capital | Buy |
| 2019-10-15 | Eingeleitet | Goldman | Neutral |
| 2019-08-14 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-09 | Bestätigt | Jefferies | Buy |
| 2019-06-17 | Eingeleitet | ROTH Capital | Buy |
| 2019-03-22 | Eingeleitet | Stifel | Buy |
Alle ansehen
Amarin Corp Adr Aktie (AMRN) Neueste Nachrichten
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma - TradingView
Amarin Corporation Plc Sponsored ADR Actuals & Estimates (NASDAQ:AMRN) - TradingView
EH3 Forecast — Price Target — Prediction for 2027 - TradingView
Net income before discontinued operations of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Price to book ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Non-operating income (total) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Current ratio of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Free cash flow per share of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Diluted earnings per share (diluted EPS) of Amarin Corporation Plc Sponsored ADR – DUS:EH3 - TradingView
Amarin Corporation Plc Sponsored ADR Revenue Breakdown – DUS:EH3 - TradingView
Hikma comments on Supreme Court of the United States' unanimous decision in favour of Hikma - Benzinga
AMRN Technical Analysis | Trend, Signals & Chart Patterns | AMARIN CORP PLC -ADR (NASDAQ:AMRN) - ChartMill
AMRNAmarin Corp ADR Short Interest - Finviz
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer - TradingView
symbol__ Stock Quote Price and Forecast - CNN
Amarin shareholders reject key proposals at annual meeting, limit equity grants - Investing.com
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised - TradingView
Amarin (NASDAQ: AMRN) investors curb new share issues and limit equity pay tools - Stock Titan
Bayer Q1 Earnings Beat Estimates, Crop Science Unit Boosts Sales - TradingView
All You Need to Know About Amarin (AMRN) Rating Upgrade to Strong Buy - Yahoo Finance
Amarin (AMRN) Loss Trend Of 24.2% Annually Tests Turnaround Narratives Heading Into Q1 - Sahm
Amarin (NASDAQ:AMRN) Surprises with Revenue Beat but EPS Falls Short Amid Restructuring Costs - ChartMill
Amarin Corp PLC (FRA:EH3) Stock Price, Trades & News - GuruFocus
Amarin Corporation Plc Sponsored ADR Trade Ideas — FWB:EH3 - TradingView
Will Amarin (AMRN) Stock Go Higher | Price at $14.77, Up 0.20%Hot Stock Picks - The Legal Advocate
AMRN Stock Soars 37.7% in a Year: Here's What You Need to Know - Finviz
Amarin Corporation Plc Sponsored ADR Trade Ideas — SWB:EH3 - TradingView
Amarin (NASDAQ: AMRN) details VASCEPA reach, Recordati deal and $70M savings - Stock Titan
Amarin's Q4 Earnings Beat Estimates, Stock Down as Revenues Miss - Finviz
Amarin Corp (NASDAQ:AMRN) Narrows Losses and Beats Adjusted EPS in Q4 2025 - ChartMill
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock? - Yahoo Finance
Amarin Corporation (AMRN) Announces Select Unaudited Financial Highlights - Finviz
AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations - Finviz
Ex-Amarin CEO Loses Suit Over Ouster After Proxy Fight - Law360
Leerink Partners raises Amarin stock price target to $12 on strong Q3 - Investing.com
FDA updates fenofibrate labels to reflect lack of cardiovascular benefit - Investing.com
Earnings call transcript: Amarin Q2 2025 sees revenue beat, stock stable - Investing.com
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Yahoo Finance
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect - Finviz
FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Finviz
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Which stocks are gapping on Tuesday? - ChartMill
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma - Finviz
KURA Stock Rises More Than 15% This Past Week: Here's Why - The Globe and Mail
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug - Finviz
Sanofi Signs a $9.5B Agreement to Acquire Blueprint Medicines - Finviz
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies - Finviz
Amarin Corp PLC Share Price ADR Each Rep 20 Ord Spon - Hargreaves Lansdown
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigat - GuruFocus
Global X Aging Population ETF Holdings - Quiver Quantitative
Finanzdaten der Amarin Corp Adr-Aktie (AMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.33%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):